Pharmaceutical

EMA CHMP provides positive opinion for ViiV’s cabotegravir

The EMA CHMP has provided a positive opinion recommending grant of marketing authorisation to ViiV Healthcare’s cabotegravir.

Jul 25, 2023 - 20:00
EMA CHMP provides positive opinion for ViiV’s cabotegravir
The EMA CHMP has provided a positive opinion recommending grant of marketing authorisation to ViiV Healthcare’s cabotegravir.
Read the original article

Tags:

Previous Article

Alvotech and Teva step up biosimilars partnership

Next Article

Golgi and Breye partner to develop P2X7 receptor antagonist programme

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA greenlights Regeneron’s Dupixent for the treatment of COPD

FDA greenlights Regeneron’s Dupixent for the treatment ...

Sep 28, 2024

Twist rolls out TCR and CAR libraries for cell therapies development

Twist rolls out TCR and CAR libraries for cell therapie...

Apr 14, 2023

Federal judge suspends FDA approval of abortion pill

Federal judge suspends FDA approval of abortion pill

Apr 7, 2023